XOMA Royalty Corporation has amended its long-standing collaboration with Takeda, returning a majority of its royalty interest in mezagitamab (TAK-079) in exchange for a diversified slice of economics across nine development-stage programs in Takeda’s externalized assets portfolio. The revision lowers XOMA’s mezagitamab economics to a low single-digit royalty and up to $13 million in milestones, down from a mid-single-digit royalty and $16.25 million in potential milestones. In return, XOMA gains entitlement to low- to mid-single-digit royalties and milestones tied to a basket that includes Neurocrine’s osavampator in major depressive disorder, Mirum’s volixibat in primary sclerosing cholangitis and primary biliary cholangitis, Oak Hill Bio’s OHB-607 for prevention of bronchopulmonary dysplasia plus five additional early-stage Oak Hill programs, and Recursion’s REC-4881 for familial adenomatous polyposis.
The move reframes XOMA’s exposure from a concentrated bet on a single Takeda asset toward a portfolio of optionality across multiple mechanisms, indications, and partners. It also raises a strategic question for 2026 pipelines: is Takeda consolidating upside in mezagitamab ahead of pivotal decisions while using its externalization platform to share risk and keep noncore programs advancing off balance sheet? For XOMA, the calculus is clear in a capital-scarce cycle: breadth of shots on goal can be more resilient than depth in one binary outcome.
The immediate relevance spans patients, payers, and HCPs in high-need categories. An AMPA positive allosteric modulator in inadequate-response MDD pushes the field beyond monoamine pathways, but payer acceptance will hinge on functional outcomes and durability in real-world settings, not just symptom scales. An IBAT inhibitor for PSC and PBC fits Mirum’s cholestatic franchise logic and, if successful, could extend the company’s footprint from pediatric to adult liver disease, inviting fresh scrutiny of comparative effectiveness and budget impact alongside emerging standards of care. Neonatal prevention of bronchopulmonary dysplasia with recombinant IGF-1/IGFBP-3 revives a long-running hypothesis in the NICU, demanding careful Medical Affairs engagement across neonatology networks and rigorous evidence on long-term safety. In FAP, a MEK1/2 inhibitor aimed at chemoprevention introduces clinical and economic questions around chronic use in a rare predisposition population where surgical management and surveillance have been the norm.
For competitors, the signal is that royalty finance is moving earlier and more granular, from single-asset royalties on commercial products to structured baskets tied to externalized pipelines. Big pharma’s externalization engines create a steady supply of financeable rights, while royalty aggregators provide non-dilutive fuel for partner-led development. That interplay is reshaping BD structures: swapping pieces of one asset for a diversified portfolio can align incentives across multiple partners and de-risk program attrition. Commercial leaders should note how such financing can accelerate late-stage readouts without large internal spend, compressing timelines to potential launch decisions. Medical Affairs teams should prepare for evidence generation that spans heterogeneous endpoints and stakeholder expectations across CNS, hepatology, neonatology, and hereditary oncology.
The next test is execution. If osavampator delivers clinically meaningful, payer-relevant outcomes, and if volixibat can carve a path in PSC/PBC where options are thin, this basket could outperform a single-asset wager. If not, XOMA’s approach will still be judged on portfolio math and cash flow resilience. The broader question for 2026: will basket-based royalty swaps become a standard tool as pharmas rebalance pipeline risk and as biotechs trade future upside for runway, or will a resurgence in capital markets pull dealmaking back to traditional single-asset economics?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
